Welcome to our dedicated page for Sight Sciences SEC filings (Ticker: SGHT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sight Sciences, Inc. (Nasdaq: SGHT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As an eyecare technology company focused on interventional glaucoma and dry eye devices, Sight Sciences uses SEC reports to communicate financial results, capital arrangements, and key corporate developments.
Investors can review Form 8-K filings where the company reports quarterly and year-to-date financial highlights, raises or updates revenue and adjusted operating expense guidance, and describes restructuring plans intended to reduce operating expenses and improve cost efficiencies. Other 8-Ks detail amendments to the company’s senior secured term loan facility with Hercules Capital, including changes to the interest-only period and tranche availability.
Filings also disclose material corporate events such as workforce reductions, executive transitions, and board changes. For example, the company has reported promotions of senior executives, entry into amended and restated employment agreements, and the resignation of directors, along with related compensation and severance terms.
These SEC documents complement the company’s press releases on clinical and reimbursement milestones for its OMNI® Surgical System, SION® Surgical System, and TearCare® System. On Stock Titan, users can access real-time updates from EDGAR and use AI-powered summaries to quickly understand the main points of lengthy filings, including quarterly (10-Q) and annual (10-K) reports when available, as well as Form 4 insider transaction reports.
AI-generated overviews help explain complex sections of Sight Sciences’ filings in plain language, highlight changes in guidance or capital structure, and point out disclosures that may be relevant to the company’s Surgical Glaucoma and Dry Eye segments. This allows readers to navigate detailed regulatory documents more efficiently while focusing on the aspects of SGHT’s business that matter most to them.
Sight Sciences is launching a restructuring plan to cut operating costs and support its path to breakeven without additional equity capital. The company will reduce headcount by 43 employees, about 20% of its global workforce, trim research and development spending, limit marketing, travel and administrative costs, and leave some open roles unfilled. It expects a cash restructuring charge of approximately $2.7 million to $3.0 million and a non-cash reduction in stock-based compensation of about $0.6 million to $1.0 million, primarily in the third quarter of 2025. The workforce plan alone is estimated to yield around $11.9 million in annualized savings. The company also announced that its Chief Commercial Officer, Matthew Link, will step down effective August 31, 2025, with his severance included in the restructuring costs. Sight Sciences reaffirmed its 2025 revenue guidance of $72.0 million to $76.0 million, reiterated that third quarter 2025 surgical glaucoma revenue is expected to be down by mid-single digits year over year, and lowered its 2025 adjusted operating expense guidance to $95 million to $99 million from $101 million to $105 million.
Sight Sciences, Inc. (SGHT) – Form 4 insider transaction
Chief Technology Officer & Director David Badawi disclosed the sale of 5,679 common shares on 03 July 2025 at an average price of $4.174 per share. The disposition was executed to satisfy statutory tax-withholding obligations generated by the vesting of restricted stock units, as noted in the filing’s footnote.
Following the sale, Badawi’s direct beneficial ownership stands at 1,831,025 shares. No derivative securities were reported, and there were no purchases.
The Form 4 indicates an automatic, non-discretionary sale (code “S”) under Rule 16a to cover taxes, which generally carries less negative signaling than voluntary open-market sales. The transaction represents approximately 0.3 % of Badawi’s post-transaction holdings and an immaterial percentage of SGHT’s total shares outstanding.
On 07/02/2025, Sight Sciences (SGHT) Chief Commercial Officer Matthew Link filed a Form 4 reporting the sale of 4,889 common shares at an average price of $4.098 per share.
The filing notes the shares were sold solely to satisfy the executive’s tax liability related to the vesting of restricted stock units. Following the transaction, Link continues to hold 832,293 shares of SGHT, retaining more than 99% of his previous direct ownership. No derivative securities were acquired or disposed of.
The sale represents a routine, low-volume insider disposition—approximately 0.6% of the executive’s holdings—and is unlikely to materially affect investor sentiment or the company’s share-price outlook.
FAQ
What is the current stock price of Sight Sciences (SGHT)?
What is the market cap of Sight Sciences (SGHT)?
